Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke - PubMed (original) (raw)

Comparative Study

Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke

A Rawanduzy et al. J Neurosurg. 1997 Dec.

Abstract

Several lines of evidence indicate that the extent of ischemic injury is not defined immediately after arterial occlusion, but that infarction expands over time. Episodes of spreading depression have been linked to this secondary increase in infarct volume. Tissue bordering the infarction fails to repolarize following spreading depression and is incorporated into the lesion. The result is that ischemic infarctions expand stepwise after each episode of spreading depression. Another line of evidence has demonstrated that gap junction blockers effectively inhibit spreading depression. These observations suggest that traffic of potentially harmful cytosolic messengers between ischemic cells and surrounding nonischemic cells might cause amplification of injury in focal stroke. It is therefore conceivable that minimizing gap junction permeability might reduce final infarct volume. To test this hypothesis, the authors pretreated rats with the gap junction blocker, octanol, before occluding the middle cerebral artery and compared the sizes of the ischemic lesions to those in rats that received the vehicle, dimethyl sulfoxide, prior to arterial occlusion. Histopathological analysis was performed 24 hours later. The 12 octanol-treated animals showed a significantly decreased mean infarction volume (80 +/- 16 mm3) compared with the nine control rats (148 +/- 9 mm3). In a separate set of experiments, the frequency of experimentally induced waves of spreading depression was evaluated after octanol treatment. Octanol pretreatment resulted in complete inhibition in two of nine animals, transient inhibition in five, and no inhibition in two. The results indicate that gap junction inhibitors, when not limited by toxicity, have significant therapeutic potential in the treatment of acute stroke.

PubMed Disclaimer

Cited by

Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds.
Ormonde S, Chou CY, Goold L, Petsoglou C, Al-Taie R, Sherwin T, McGhee CN, Green CR. Ormonde S, et al. J Membr Biol. 2012 Jul;245(7):381-8. doi: 10.1007/s00232-012-9460-4. Epub 2012 Jul 15. J Membr Biol. 2012. PMID: 22797940 Clinical Trial.
Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction.
Rodríguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D. Rodríguez-Sinovas A, et al. Heart Fail Rev. 2007 Dec;12(3-4):207-16. doi: 10.1007/s10741-007-9039-9. Heart Fail Rev. 2007. PMID: 17530396 Review.
Global ischemia-induced increases in the gap junctional proteins connexin 32 (Cx32) and Cx36 in hippocampus and enhanced vulnerability of Cx32 knock-out mice.
Oguro K, Jover T, Tanaka H, Lin Y, Kojima T, Oguro N, Grooms SY, Bennett MV, Zukin RS. Oguro K, et al. J Neurosci. 2001 Oct 1;21(19):7534-42. doi: 10.1523/JNEUROSCI.21-19-07534.2001. J Neurosci. 2001. PMID: 11567043 Free PMC article.
A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window.
Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. Yrjänheikki J, et al. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13496-500. doi: 10.1073/pnas.96.23.13496. Proc Natl Acad Sci U S A. 1999. PMID: 10557349 Free PMC article.
Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke.
Liu Z, Chopp M. Liu Z, et al. Prog Neurobiol. 2016 Sep;144:103-20. doi: 10.1016/j.pneurobio.2015.09.008. Epub 2015 Oct 9. Prog Neurobiol. 2016. PMID: 26455456 Free PMC article. Review.

Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke - PubMed (original) (raw)